AstraZeneca Reports Results of Breztri Aerosphere in P-III ETHOS Study for Chronic Obstructive Pulmonary Disease
Shots:
- The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6mcg) vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate 14.4/9.6mcg) and PT009 (budesonide/formoterol fumarate 320/9.6mcg) in symptomatic patients with mod. to sev. COPD
- The P-III ETHOS study resulted in meeting its 1EPs i/e- reduction in the rate of mod./sev. exacerbations at both standard & half dose of budesonide. The P-III ETHOS study follows KRONOS study which also resulted in reduction of exacerbation in COPD patients
- Breztri Aerosphere is an approved triple combination therapy in Japan and is under regulatory review in the US- China and EU and Bevespi Aerosphere (FD) is dual bronchodilator- administered in a pressurized metered-dose inhaler utilizing Aerosphere delivery technology
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com